BONESUPPORT HOLDING AB (2B4) Price & Analysis

Compare

5 Followers

2B4 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€20.50 - €39.42

Previous CloseN/A

Volume165.00

Average Volume (3M)23.00

Market Cap

€1.60B

Enterprise ValueN/A

Total Cash (Recent Filing)€267.13M

Total Debt (Recent Filing)kr12.66M

Price to Earnings (P/E)151.8

Beta0.15

Next Earnings

Jul 15, 2025

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding65,859,190

10 Day Avg. Volume48

30 Day Avg. Volume23

Financial Highlights & Ratios

PEG Ratio-19.93

Price to Book (P/B)27.56

Price to Sales (P/S)0.00

P/FCF Ratio225.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

BONESUPPORT HOLDING AB News

PremiumCompany Announcements

BONESUPPORT Announces CEO Transition to Drive Future Growth

27d ago

PremiumCompany Announcements

BONESUPPORT Announces Leadership Transition with New CEO Appointment

27d ago

PremiumCompany Announcements

BONESUPPORT Announces Leadership Transition with New CEO Appointment

27d ago

PremiumCompany Announcements

BONESUPPORT Announces CEO Transition to Propel Future Growth

27d ago

PremiumCompany Announcements

BONESUPPORT Announces CEO Transition to Drive Future Growth

27d ago

PremiumCompany Announcements

BONESUPPORT Announces Leadership Transition with New CEO Appointment

27d ago

PremiumCompany Announcements

BONESUPPORT Announces Leadership Transition with New CEO Appointment

27d ago

PremiumCompany Announcements

BONESUPPORT Announces Leadership Transition with New CEO Appointment

27d ago

See All DE:2B4 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

11.62%

Mutual Funds

― Other Institutional Investors

82.44% Public Companies and

Individual Investors

Detailed Ownership Overview >

2B4 FAQ

What was BONESUPPORT HOLDING AB’s price range in the past 12 months?

BONESUPPORT HOLDING AB lowest stock price was €20.50 and its highest was €39.42 in the past 12 months.

What is BONESUPPORT HOLDING AB’s market cap?

BONESUPPORT HOLDING AB’s market cap is €1.60B.

When is BONESUPPORT HOLDING AB’s upcoming earnings report date?

BONESUPPORT HOLDING AB’s upcoming earnings report date is Jul 15, 2025 which is in 51 days.

How were BONESUPPORT HOLDING AB’s earnings last quarter?

BONESUPPORT HOLDING AB released its earnings results on Apr 24, 2025. The company reported €0.015 earnings per share for the quarter, beating the consensus estimate of N/A by €0.015.

Is BONESUPPORT HOLDING AB overvalued?

According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BONESUPPORT HOLDING AB pay dividends?

BONESUPPORT HOLDING AB does not currently pay dividends.

What is BONESUPPORT HOLDING AB’s EPS estimate?

BONESUPPORT HOLDING AB’s EPS estimate is 0.06.

How many shares outstanding does BONESUPPORT HOLDING AB have?

BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.

What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?

BONESUPPORT HOLDING AB reported an EPS of €0.015 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.

Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?

Currently, no hedge funds are holding shares in DE:2B4

Company Description

BONESUPPORT HOLDING AB

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.

2B4 Company Deck

2B4 Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Bonesupport's Q3 2024 earnings call highlighted robust sales growth, particularly for CERAMENT G in the U.S., and successful clinical outcomes from the SOLARIO study. While there were some challenges in Europe and currency impacts, the overall sentiment is largely positive due to strong market performance and promising future prospects.Read More>

2B4 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2021","6":"May<br/>2021","9":"Aug<br/>2021","12":"Oct<br/>2021","25":"Oct<br/>2022"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,3.4984615384615383,3.206923076923077,2.9153846153846157,2.623846153846154,2.332307692307692,2.040769230769231,1.7492307692307696,1.4576923076923078,1.166153846153846,0.8746153846153848,0.5830769230769235,0.29153846153846175,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.28,"date":1604188800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.28,"date":1606780800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.28,"date":1609459200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.28,"date":1612137600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.7,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.75,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.32,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.96,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.19,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.69,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.68,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.79,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.79,"date":1633046400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >